These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158 [TBL] [Abstract][Full Text] [Related]
6. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition. Gurzu S; Szentirmay Z; Toth E; Bara T; Bara T; Jung I PLoS One; 2013; 8(3):e57699. PubMed ID: 23469219 [TBL] [Abstract][Full Text] [Related]
7. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188 [TBL] [Abstract][Full Text] [Related]
8. Mutational analysis and clinical correlation of metastatic colorectal cancer. Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602 [TBL] [Abstract][Full Text] [Related]
9. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report. El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337 [TBL] [Abstract][Full Text] [Related]
10. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873 [TBL] [Abstract][Full Text] [Related]
11. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin. Soliman ML; Tiwari A; Zhao Q World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485 [TBL] [Abstract][Full Text] [Related]
12. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma]. Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726 [TBL] [Abstract][Full Text] [Related]
13. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Lin F; Shi J; Zhu S; Chen Z; Li A; Chen T; Wang HL; Liu H Arch Pathol Lab Med; 2014 Aug; 138(8):1015-26. PubMed ID: 24437456 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210 [TBL] [Abstract][Full Text] [Related]
15. A comprehensive study of nondysplastic and dysplastic serrated polyps of the vermiform appendix. Yantiss RK; Panczykowski A; Misdraji J; Hahn HP; Odze RD; Rennert H; Chen YT Am J Surg Pathol; 2007 Nov; 31(11):1742-53. PubMed ID: 18059232 [TBL] [Abstract][Full Text] [Related]
16. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
17. Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases. Kwon MJ; Min BH; Lee SM; Park HY; Kang SY; Ha SY; Lee JH; Kim JJ; Park CK; Kim KM Histol Histopathol; 2013 Apr; 28(4):453-62. PubMed ID: 23404616 [TBL] [Abstract][Full Text] [Related]
18. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350 [TBL] [Abstract][Full Text] [Related]
19. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E; Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376 [TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. Zhang X; Wang Y; Gao N; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]